References
- Hersh A L, Stefanick M L, Stafford R S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47–53
- Harman S M, Brinton E A, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3–12
- Gambacciani M, Ciaponi M, Genazzani A R. The HRT misuse and the osteoporosis epidemic: a possible future scenario. Climacteric 2007; 10: 273–275
- Cauley J A, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. JAMA 2003; 290: 1729–1738
- Anderson G L, Limacher M, Assaf A R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
- Bagger Y Z, Tankó L, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728–735
- Bagger Y Z, Tankó L, Alexandersen P, Qin G, Christiansen C, for the PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005; 12: 12–17
- Muscat Baron Y, Brincat M B, Galea R, Calleja N. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 2007; 10: 314–319
- Ausmanas M K, Holinka C F, Yu S L, Christiansen C. Effects of three doses of conjugated estrogens/medroxyprogesteone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. Climacteric 2007; 10: 306–313
- Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The PAN-Asia Menopause (PAM) study. Maturitas 2005; 52: 35–51
- Taechakraichana N, Holinka C F, Haines C J, Subramaniam R, Tian X W, Ausmanas M. Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study. Climacteric 2007; 10: 225–237
- Karsdal M A, Tanko L B, Riis B J, et al. Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA?. Osteoarthritis Cartilage 2006; 14: 617–624
- Sorensen M G, Henriksen K, Dziegiel M H, Tanko L B, Karsdal M A. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 2006; 25: 475–483
- Oestergaard S, Sondergaard B C, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006; 54: 2441–2451
- Ham K D, Loeser R F, Lindgren B R, Carlson C S. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002; 46: 1956–1964
- Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 209–215
- Reijman M, Hazes J MW, Bierma-Zeinstra S MA, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 2471–2478
- Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006; 65: 1639–1644
- Christgau S, Tanko L B, Cloos P A, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004; 11: 508–518